Talphera (TLPH) Free Cash Flow (2010 - 2026)
Talphera (TLPH) posted Free Cash Flow of -$3.9 million for Q2 2026, down 15.41% on a QoQ basis from -$3.4 million in Q1 2026, and down 33.11% year-over-year from -$5.9 million in Q2 2025.
Analysis
Talphera (TLPH) Free Cash Flow (2010 - 2026) Analysis & Trends
Talphera has reported Free Cash Flow for 17 years, with the latest figure at -$3.9 million in Q2 2026.
- On a quarterly basis, Free Cash Flow fell 33.11% year-over-year to -$3.9 million in Q2 2026; TTM through Jun 2026 was -$12.3 million, a 5.7% decrease from a year earlier, with the FY2025 full-year figure at -$11.4 million, up 10.4% from the prior year.
- Free Cash Flow was -$3.9 million for Q2 2026 at Talphera, down from -$3.4 million in the prior quarter.
- The five-year high for Free Cash Flow was -$2.3 million in Q4 2024, with the low at -$9.0 million in Q1 2022.
- Average Free Cash Flow over 5 years is -$4.3 million, with a median of -$3.7 million recorded in 2025.
- The sharpest annual moves came in 2024 and 2026: Free Cash Flow surged 46.11% in 2024, then sank 33.11% in 2026.
- Over 5 years, Free Cash Flow stood at -$5.5 million in 2022, then gained by 27.69% to -$3.9 million in 2023, then soared by 42.92% to -$2.3 million in 2024, then dropped by 8.07% to -$2.4 million in 2025, then sank by 61.08% to -$3.9 million in 2026.
- The last three Free Cash Flow figures came in at -$3.9 million (Q2 2026), -$3.4 million (Q1 2026), and -$2.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 3.49 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.01 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 572.80 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -563.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 408.00 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -268.64 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | -3.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.92 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -2.44 Mn |
| Sep 30, 2025 | -2.51 Mn |
| Jun 30, 2025 | -2.95 Mn |
| Mar 31, 2025 | -3.47 Mn |
| Dec 31, 2024 | -2.25 Mn |
| Sep 30, 2024 | -2.94 Mn |
| Jun 30, 2024 | -4.61 Mn |
| Mar 31, 2024 | -2.88 Mn |
| Dec 31, 2023 | -3.95 Mn |
| Sep 30, 2023 | -2.96 Mn |
| Jun 30, 2023 | -5.33 Mn |
| Mar 31, 2023 | -5.35 Mn |
| Dec 31, 2022 | -5.46 Mn |
| Sep 30, 2022 | -5.40 Mn |
| Jun 30, 2022 | -8.82 Mn |
| Mar 31, 2022 | -9.02 Mn |
| Dec 31, 2021 | -8.03 Mn |
| Sep 30, 2021 | -4.13 Mn |